POST Online Media Lite Edition



 

Massachusetts AG Healey sues Publicis for role in fueling opioid crisis

Christian Fernsby |
Massachusetts Attorney General Maura Healey today filed a lawsuit against Publicis Health, LLC, a significant player in the American drug marketing industry, alleging it designed and deployed unfair and deceptive marketing schemes to help Purdue Pharma sell more OxyContin, including in Massachusetts.

Article continues below



Topics: MASSACHUSETTS    PUBLICIS   

In a complaint filed in Suffolk Superior Court today, AG Healey alleges that from 2010 to 2019, Publicis – a subsidiary of global advertising conglomerate Publicis Groupe – partnered with Purdue on dozens of contracts, collecting more than $50 million in exchange for marketing schemes to get doctors to prescribe Purdue’s opioids to more patients, in higher doses, for longer periods of time.

“Responsibility for the opioid crisis runs across the industry, from Purdue and the Sacklers, to consultants and partners like McKinsey and Publicis,” said AG Healey.

“Publicis convinced doctors to prescribe more OxyContin to more patients as the opioid epidemic was raging. As a result, patients in Massachusetts suffered, overdosed, and died, while Publicis collected tens of millions of dollars.”

The AG’s complaint alleges that, over its decade-long partnership with Purdue, Publicis engaged in myriad unfair and deceptive strategies that influenced OxyContin prescribing across the nation, including in Massachusetts. In particular, Publicis:

Devised marketing strategies to combat prescribers’ hesitancy to prescribe OxyContin, including materials used to train and assist Purdue sales reps in detailing doctors;

Wrote and facilitated the delivery of thousands of unfair and deceptive emails to prescribers, including messages designed to get doctors to convert more patients to OxyContin from lower dose, short-acting opioids, and increase existing patients’ doses and duration on the drug, without regard for the increased risk;

Developed strategies to counter the 2016 CDC Guideline for Prescribing Opioids for Chronic Pain and maintain OxyContin prescribing levels;

Told Purdue how to target the most dangerous high prescribers; and

Helped Purdue increase the number of patients on OxyContin by placing ads for OxyContin right in patients’ electronic medical records, including at the point-of-prescribing.

Publicis also partnered with Purdue’s internal marketing team to “humanize” the OxyContin brand by creating patient vignettes to get doctors to recognize patients who could be started on OxyContin. Publicis developed one patient vignette, “James,” age 40, to target a younger demographic.

Publicis designed the “James” patient example to have his dose increased from 10 mg to 15 mg to 20 mg, in a period of just three weeks. Publicis devised marketing plans to deliver patient vignettes like James to prescribers, including through Purdue sales rep visits with doctors.

Publicis carried out the misconduct alleged in the complaint under several trade names, including Rosetta and Razorfish Health.

This matter is being handled by Assistant Attorneys General Jenny Wojewoda, Sandy Alexander, and Ethan Marks, Senior Enforcement Counsel Gillian Feiner, Health Care Division Chief Eric Gold, and Paralegals Philipp Nowak and Indira Rao of the AG’s Health Care and Fair Competition Bureau, with assistance from Senior Investigator Marlee Greer of the AG’s Civil Investigations Division.


What to read next

Publicis to buy Sapient for $3.7 billion in cash
Unredacted information shows unbelievable greed of Teva Pharmaceuticals
Governor Cuomo announces first insurance fraud action against opioid manufacturer Mallinckrodt